# Hebang Biology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hebang-biology

- Industry: Pharmaceuticals
- Headquarters: Wuxi, China
- Total disclosed funding: $27M
- Latest round: Series E (Jan 1, 2015)
- Investors on record: 5

## About

Established in 2006 and based in Wuxi, China, Hebang Biology operates as a biotech pharmaceutical company dedicated to the research and development of genetically engineered protein drugs. In January 2015, the company raised CNY 28 million of series E funding from new investor NewMargin Ventures.

The company mainly provides genetically engineered protein drugs. Products are used to treat diabetes, tumors, congestive heart failure, viral chronic hepatitis B, hepatitis C, etc.

The company generates revenue by providing genetically engineered protein drugs.

## Funding rounds

- Series E, Jan 1, 2015, $4.6M — NewMargin Ventures
- Series D, Mar 4, 2014, $23M — Jolmo Capital
- Series C, Apr 1, 2010 — Grand Yangtze Capital
- Series A, Dec 31, 2006 — Wuxi Huading Venture Capital, Wuxi High-tech Venture Capital

## Investors

- Wuxi Huading Venture Capital (https://capitalatlas.ai/funds/wuxi-huading-venture-capital) — Series A
- Wuxi High-tech Venture Capital — Series A
- Grand Yangtze Capital (https://capitalatlas.ai/funds/grand-yangtze-capital) — Series C
- Jolmo Capital (https://capitalatlas.ai/funds/jolmo-capital) — Series D
- NewMargin Ventures (https://capitalatlas.ai/funds/newmargin-ventures) — Series E